![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Time to Viral Suppression Does not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir
|
|
|
Reported by Jules Levin
Infectious Diseases Society of America, October 3-7, 2018, San Francisco, California  
Christoph Sarrazin1, Jordan J Feld2, Douglas E Dylla3, Sanjeev Arora4, David Victor III5, Yiran B Hu3, Stanley Wang3, Federico J Mensa3, David Wyles6
1JW Goethe University Hospital, Frankfurt, Germany and St. Josefs-Hospital, Wiesbaden, Germany; 2Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada; 3AbbVie Inc., North Chicago, Illinois, United States; 4University of New Mexico, Albuquerque, New Mexico, United States; 5Houston Methodist Hospital, Houston, Texas, United States;
6Denver Health Medical Center, Denver, Colorado, United States
![1009181](../images%20/100818/100918-12/1009181.gif)
![1009182](../images%20/100818/100918-12/1009182.gif)
![1009183](../images%20/100818/100918-12/1009183.gif)
![1009184](../images%20/100818/100918-12/1009184.gif)
![1009185](../images%20/100818/100918-12/1009185.gif)
![1009186](../images%20/100818/100918-12/1009186.gif)
![1009187](../images%20/100818/100918-12/1009187.gif)
![1009188](../images%20/100818/100918-12/1009188.gif)
![1009189](../images%20/100818/100918-12/1009189.gif)
![10091810](../images%20/100818/100918-12/10091810.gif)
![10091811](../images%20/100818/100918-12/10091811.gif)
![10091811](../images%20/100818/100918-12/10091811.gif)
![10091812](../images%20/100818/100918-12/10091812.gif)
![10091813](../images%20/100818/100918-12/10091813.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|